Aspirin use and risk for lung cancer: A meta-analysis

S. W. Oh, S. K. Myung, J. Y. Park, C. M. Lee, H. T. Kwon

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. Patients and methods: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. Results: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95% confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95% CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95% CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07). Conclusions: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.

Original languageEnglish
Pages (from-to)2456-2465
Number of pages10
JournalAnnals of Oncology
Volume22
Issue number11
DOIs
StatePublished - 1 Nov 2011

Fingerprint

Aspirin
Meta-Analysis
Lung Neoplasms
Confidence Intervals
Odds Ratio
Cohort Studies
Case-Control Studies
Prospective Studies
Bibliography
Libraries
Observational Studies
Randomized Controlled Trials

Keywords

  • Aspirin
  • Lung cancer
  • Meta-analysis
  • Nsaids

Cite this

Oh, S. W. ; Myung, S. K. ; Park, J. Y. ; Lee, C. M. ; Kwon, H. T. / Aspirin use and risk for lung cancer : A meta-analysis. In: Annals of Oncology. 2011 ; Vol. 22, No. 11. pp. 2456-2465.
@article{092b339b306d48ea9351cd110044ab11,
title = "Aspirin use and risk for lung cancer: A meta-analysis",
abstract = "Background: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. Patients and methods: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. Results: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95{\%} confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95{\%} CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95{\%} CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95{\%} CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95{\%} CI 0.76-1.07). Conclusions: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.",
keywords = "Aspirin, Lung cancer, Meta-analysis, Nsaids",
author = "Oh, {S. W.} and Myung, {S. K.} and Park, {J. Y.} and Lee, {C. M.} and Kwon, {H. T.}",
year = "2011",
month = "11",
day = "1",
doi = "10.1093/annonc/mdq779",
language = "English",
volume = "22",
pages = "2456--2465",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "11",

}

Aspirin use and risk for lung cancer : A meta-analysis. / Oh, S. W.; Myung, S. K.; Park, J. Y.; Lee, C. M.; Kwon, H. T.

In: Annals of Oncology, Vol. 22, No. 11, 01.11.2011, p. 2456-2465.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aspirin use and risk for lung cancer

T2 - A meta-analysis

AU - Oh, S. W.

AU - Myung, S. K.

AU - Park, J. Y.

AU - Lee, C. M.

AU - Kwon, H. T.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Background: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. Patients and methods: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. Results: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95% confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95% CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95% CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07). Conclusions: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.

AB - Background: Aspirin has received increasing attention owing to its potential as a chemopreventive agent against lung cancer. Previous observational studies have reported inconsistent findings on this issue. We investigated the association between aspirin use and risk for lung cancer by conducting a meta-analysis. Patients and methods: Relevant studies were identified by searching Medline, EMBASE, and Cochrane Library to December 2009. We also reviewed relevant bibliographies from the retrieved articles. Two authors independently extracted data and assessed study quality. Disagreements were resolved by consensus. Results: Fifteen studies (six case-control studies and nine prospective cohort studies) were included in the final meta-analysis. When all studies were pooled, the odds ratio (OR) of aspirin use for lung cancer risk was 0.86 [95% confidence interval (CI) 0.76-0.98]. In subgroup meta-analyses, there was no association between aspirin use and lung cancer risk among cohort studies (relative risk, 0.97; 95% CI 0.87-1.08), while there was a significant association among case-control studies (OR, 0.74; 95% CI 0.57-0.99). In a subgroup meta-analysis by quality of study methodology, a significant protective effect of aspirin use on lung cancer was observed only among eight low-quality studies (OR, 0.82; 95% CI 0.68-0.99), but not among seven high-quality studies (OR, 0.90; 95% CI 0.76-1.07). Conclusions: Overall, the findings of this meta-analysis support that there was no association between aspirin use and lung cancer risk. Our findings should be confirmed in future prospective cohort studies or randomized, controlled trials.

KW - Aspirin

KW - Lung cancer

KW - Meta-analysis

KW - Nsaids

UR - http://www.scopus.com/inward/record.url?scp=80155174233&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq779

DO - 10.1093/annonc/mdq779

M3 - Article

C2 - 21385885

AN - SCOPUS:80155174233

VL - 22

SP - 2456

EP - 2465

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 11

ER -